OALib Journal期刊
ISSN: 2333-9721
费用：99美元

投递稿件

查看量	下载量

相关文章
更多...

Cancers 2013

Tumor Metabolism of Malignant Gliomas

DOI: 10.3390/cancers5041469

Peng Ru,Terence M. Williams,Arnab Chakravarti,Deliang Guo

Keywords: glioblastoma, tumor metabolism, SREBP-1, LDLR, LXR, glucose, lipids, cholesterol

Full-Text Cite this paper Add to My Lib

Abstract:

Constitutively activated oncogenic signaling via genetic mutations such as in the EGFR/PI3K/Akt and Ras/RAF/MEK pathways has been recognized as a major driver for tumorigenesis in most cancers. Recent insights into tumor metabolism have further revealed that oncogenic signaling pathways directly promote metabolic reprogramming to upregulate biosynthesis of lipids, carbohydrates, protein, DNA and RNA, leading to enhanced growth of human tumors. Therefore, targeting cell metabolism has become a novel direction for drug development in oncology. In malignant gliomas, metabolism pathways of glucose, glutamine and lipid are significantly reprogrammed. Moreover, molecular mechanisms causing these metabolic changes are just starting to be unraveled. In this review, we will summarize recent studies revealing critical gene alterations that lead to metabolic changes in malignant gliomas, and also discuss promising therapeutic strategies via targeting the key players in metabolic regulation.

References

[1]	Kaplan, R.S. Supratentorial malignant gliomas: Risk patterns and therapy. J. Natl. Cancer. Inst. 1993, 85, 690–691, doi:10.1093/jnci/85.9.690.
[2]	Furnari, F.B.; Fenton, T.; Bachoo, R.M.; Mukasa, A.; Stommel, J.M.; Stegh, A.; Hahn, W.C.; Ligon, K.L.; Louis, D.N.; Brennan, C.; et al. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes. Dev. 2007, 21, 2683–2710, doi:10.1101/gad.1596707.
[3]	Wen, P.Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359, 492–507.
[4]	Dunn, G.P.; Rinne, M.L.; Wykosky, J.; Genovese, G.; Quayle, S.N.; Dunn, I.F.; Agarwalla, P.K.; Chheda, M.G.; Campos, B.; Wang, A.; et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012, 26, 756–784, doi:10.1101/gad.187922.112.
[5]	Seshacharyulu, P.; Ponnusamy, M.P.; Haridas, D.; Jain, M.; Ganti, A.K.; Batra, S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16, 15–31, doi:10.1517/14728222.2011.648617.
[6]	Mellinghoff, I.K.; Wang, M.Y.; Vivanco, I.; Haas-Kogan, D.A.; Zhu, S.; Dia, E.Q.; Lu, K.V.; Yoshimoto, K.; Huang, J.H.; Chute, D.J.; et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 2005, 353, 2012–2024, doi:10.1056/NEJMoa051918.
[7]	Wheeler, D.L.; Dunn, E.F.; Harari, P.M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 2010, 7, 493–507, doi:10.1038/nrclinonc.2010.97.
[8]	Chakravarti, A.; Wang, M.; Robins, H.I.; Lautenschlaeger, T.; Curran, W.J.; Brachman, D.G.; Schultz, C.J.; Choucair, A.; Dolled-Filhart, M.; Christiansen, J.; et al. RTOG 0211: A phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int. J. Radiat. Oncol. Biol. Phys. 2013, 85, 1206–1211, doi:10.1016/j.ijrobp.2012.10.008.
[9]	Tanaka, K.; Babic, I.; Nathanson, D.; Akhavan, D.; Guo, D.; Gini, B.; Dang, J.; Zhu, S.; Yang, H.; de Jesus, J.; et al. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov. 2011, 1, 524–538, doi:10.1158/2159-8290.CD-11-0124.
[10]	Marin-Valencia, I.; Yang, C.; Mashimo, T.; Cho, S.; Baek, H.; Yang, X.L.; Rajagopalan, K.N.; Maddie, M.; Vemireddy, V.; Zhao, Z.; et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012, 15, 827–837, doi:10.1016/j.cmet.2012.05.001.
[11]	Martini, M.; Ciraolo, E.; Gulluni, F.; Hirsch, E. Targeting PI3K in Cancer: Any Good News? Front. Oncol. 2013, 3, 108.
[12]	Courtney, K.D.; Corcoran, R.B.; Engelman, J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28, 1075–1083, doi:10.1200/JCO.2009.25.3641.
[13]	Chakravarti, A.; Zhai, G.; Suzuki, Y.; Sarkesh, S.; Black, P.M.; Muzikansky, A.; Loeffler, J.S. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol. 2004, 22, 1926–1933, doi:10.1200/JCO.2004.07.193.
[14]	Ferrara, N. VEGF as a therapeutic target in cancer. Oncology 2005, 69, 11–16, doi:10.1159/000088479.
[15]	Jun, H.J.; Acquaviva, J.; Chi, D.; Lessard, J.; Zhu, H.; Woolfenden, S.; Bronson, R.T.; Pfannl, R.; White, F.; Housman, D.E.; et al. Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene 2012, 31, 3039–3050, doi:10.1038/onc.2011.474.
[16]	Huang, T.T.; Sarkaria, S.M.; Cloughesy, T.F.; Mischel, P.S. Targeted therapy for malignant glioma patients: Lessons learned and the road ahead. Neurotherapeutics 2009, 6, 500–512, doi:10.1016/j.nurt.2009.04.008.
[17]	DeBerardinis, R.J.; Lum, J.J.; Hatzivassiliou, G.; Thompson, C.B. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7, 11–20, doi:10.1016/j.cmet.2007.10.002.
[18]	Deberardinis, R.J.; Thompson, C.B. Cellular metabolism and disease: What do metabolic outliers teach us? Cell 2012, 148, 1132–1144, doi:10.1016/j.cell.2012.02.032.
[19]	Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009, 324, 1029–1033, doi:10.1126/science.1160809.
[20]	Schulze, A.; Harris, A.L. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012, 491, 364–373, doi:10.1038/nature11706.
[21]	Wolf, A.; Agnihotri, S.; Guha, A. Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget 2010, 1, 552–562.
[22]	Maher, E.A.; Marin-Valencia, I.; Bachoo, R.M.; Mashimo, T.; Raisanen, J.; Hatanpaa, K.J.; Jindal, A.; Jeffrey, F.M.; Choi, C.; Madden, C.; et al. Metabolism of [U-(13) C]glucose in human brain tumors in vivo. NMR Biomed. 2012, 25, 1234–1244, doi:10.1002/nbm.2794.
[23]	Yang, C.; Sudderth, J.; Dang, T.; Bachoo, R.M.; McDonald, J.G.; DeBerardinis, R.J. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009, 69, 7986–7993.
[24]	Bell, E.H.; Guo, D. Biomarkers for malignant gliomas. Malig. Gliomas Radiat. Med. Rounds 2012, 3, 389–357.
[25]	Guo, D.; Bell, E.H.; Chakravarti, A. Lipid metabolism emerges as a promising target for malignant glioma therapy. CNS Oncol. 2013, 2, 289–299, doi:10.2217/cns.13.20.
[26]	Guo, D.; Cloughesy, T.F.; Radu, C.G.; Mischel, P.S. AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. Cell Cycle 2010, 9, 211–212, doi:10.4161/cc.9.2.10540.
[27]	Guo, D.; Hildebrandt, I.J.; Prins, R.M.; Soto, H.; Mazzotta, M.M.; Dang, J.; Czernin, J.; Shyy, J.Y.; Watson, A.D.; Phelps, M.; et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc. Natl. Acad. Sci. USA 2009, 106, 12932–12937, doi:10.1073/pnas.0906606106.
[28]	Guo, D.; Prins, R.M.; Dang, J.; Kuga, D.; Iwanami, A.; Soto, H.; Lin, K.Y.; Huang, T.T.; Akhavan, D.; Hock, M.B.; et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci. Signal. 2009, 2, ra82, doi:10.1126/scisignal.2000446.
[29]	Guo, D.; Reinitz, F.; Youssef, M.; Hong, C.; Nathanson, D.; Akhavan, D.; Kuga, D.; Amzajerdi, A.N.; Soto, H.; Zhu, S.; et al. An LXR agonist promotes GBM cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer. Discov. 2011, 1, 442–456, doi:10.1158/2159-8290.CD-11-0102.
[30]	Kefas, B.; Comeau, L.; Erdle, N.; Montgomery, E.; Amos, S.; Purow, B. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro. Oncol. 2010, 12, 1102–1112, doi:10.1093/neuonc/noq080.
[31]	Yang, W.; Xia, Y.; Cao, Y.; Zheng, Y.; Bu, W.; Zhang, L.; You, M.J.; Koh, M.Y.; Cote, G.; Aldape, K.; et al. EGFR-induced and PKCepsilon monoubiquitylation-dependent NF-kappaB activation upregulates PKM2 expression and promotes tumorigenesis. Mol. Cell 2012, 48, 771–784, doi:10.1016/j.molcel.2012.09.028.
[32]	Dang, L.; Jin, S.; Su, S.M. IDH mutations in glioma and acute myeloid leukemia. Trends Mol. Med. 2010, 16, 387–397, doi:10.1016/j.molmed.2010.07.002.
[33]	Williams, K.J.; Argus, J.P.; Zhu, Y.; Wilks, M.Q.; Marbois, B.N.; York, A.G.; Kidani, Y.; Pourzia, A.L.; Akhavan, D.; Lisiero, D.N.; et al. An Essential Requirement for the SCAP/SREBP Signaling Axis to Protect Cancer Cells from Lipotoxicity. Cancer Res. 2013, 73, 2850–2862, doi:10.1158/0008-5472.CAN-13-0382-T.
[34]	Ainscow, E.K.; Brand, M.D. Top-down control analysis of ATP turnover, glycolysis and oxidative phosphorylation in rat hepatocytes. Eur. J. Biochem. 1999, 263, 671–685, doi:10.1046/j.1432-1327.1999.00534.x.
[35]	Lopez-Lazaro, M. The warburg effect: Why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med Chem. 2008, 8, 305–312, doi:10.2174/187152008783961932.
[36]	Warburg, O. On the origin of cancer cells. Science 1956, 123, 309–314.
[37]	Warburg, O. On respiratory impairment in cancer cells. Science 1956, 124, 269–270.
[38]	Ward, P.S.; Thompson, C.B. Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21, 297–308, doi:10.1016/j.ccr.2012.02.014.
[39]	Koppenol, W.H.; Bounds, P.L.; Dang, C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11, 325–337, doi:10.1038/nrc3038.
[40]	Lunt, S.Y.; Vander Heiden, M.G. Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell. Dev. Biol. 2011, 27, 441–464, doi:10.1146/annurev-cellbio-092910-154237.
[41]	Babic, I.; Anderson, E.S.; Tanaka, K.; Guo, D.; Masui, K.; Li, B.; Zhu, S.; Gu, Y.; Villa, G.R.; Akhavan, D.; et al. EGFR Mutation-Induced Alternative Splicing of Max Contributes to Growth of Glycolytic Tumors in Brain Cancer. Cell Metab. 2013, 17, 1000–1008, doi:10.1016/j.cmet.2013.04.013.
[42]	Kim, J.W.; Dang, C.V. Multifaceted roles of glycolytic enzymes. Trends Biochem. Sci. 2005, 30, 142–150, doi:10.1016/j.tibs.2005.01.005.
[43]	Wilson, J.E. Isozymes of mammalian hexokinase: Structure, subcellular localization and metabolic function. J. Exp. Biol. 2003, 206, 2049–2057, doi:10.1242/jeb.00241.
[44]	Postic, C.; Shiota, M.; Magnuson, M.A. Cell-specific roles of glucokinase in glucose homeostasis. Recent Prog. Horm. Res. 2001, 56, 195–217, doi:10.1210/rp.56.1.195.
[45]	Printz, R.L.; Magnuson, M.A.; Granner, D.K. Mammalian glucokinase. Annu. Rev. Nutr. 1993, 13, 463–496, doi:10.1146/annurev.nu.13.070193.002335.
[46]	Wolf, A.; Agnihotri, S.; Micallef, J.; Mukherjee, J.; Sabha, N.; Cairns, R.; Hawkins, C.; Guha, A. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J. Exp. Med. 2011, 208, 313–326, doi:10.1084/jem.20101470.
[47]	Agnihotri, S.; Wolf, A.; Munoz, D.M.; Smith, C.J.; Gajadhar, A.; Restrepo, A.; Clarke, I.D.; Fuller, G.N.; Kesari, S.; Dirks, P.B.; et al. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. J. Exp. Med. 2011, 208, 689–702, doi:10.1084/jem.20102099.
[48]	Wolf, A.; Agnihotri, S.; Munoz, D.; Guha, A. Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. Neurobiol. Dis. 2011, 44, 84–91, doi:10.1016/j.nbd.2011.06.007.
[49]	Mazurek, S.; Boschek, C.B.; Hugo, F.; Eigenbrodt, E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005, 15, 300–308, doi:10.1016/j.semcancer.2005.04.009.
[50]	Clower, C.V.; Chatterjee, D.; Wang, Z.; Cantley, L.C.; Vander Heiden, M.G.; Krainer, A.R. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc. Natl. Acad. Sci. USA 2010, 107, 1894–1899.
[51]	Mazurek, S. Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 2011, 43, 969–980, doi:10.1016/j.biocel.2010.02.005.
[52]	Christofk, H.R.; Vander Heiden, M.G.; Harris, M.H.; Ramanathan, A.; Gerszten, R.E.; Wei, R.; Fleming, M.D.; Schreiber, S.L.; Cantley, L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452, 230–233, doi:10.1038/nature06734.
[53]	Yang, W.; Xia, Y.; Hawke, D.; Li, X.; Liang, J.; Xing, D.; Aldape, K.; Hunter, T.; Alfred Yung, W.K.; Lu, Z. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012, 150, 685–696, doi:10.1016/j.cell.2012.07.018.
[54]	Yang, W.; Xia, Y.; Ji, H.; Zheng, Y.; Liang, J.; Huang, W.; Gao, X.; Aldape, K.; Lu, Z. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 2011, 480, 118–122.
[55]	Yang, W.; Zheng, Y.; Xia, Y.; Ji, H.; Chen, X.; Guo, F.; Lyssiotis, C.A.; Aldape, K.; Cantley, L.C.; Lu, Z. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 2012, 14, 1295–1304, doi:10.1038/ncb2629.
[56]	Liu, Y.; Li, Y.M.; Tian, R.F.; Liu, W.P.; Fei, Z.; Long, Q.F.; Wang, X.A.; Zhang, X. The expression and significance of HIF-1alpha and GLUT-3 in glioma. Brain Res. 2009, 1304, 149–154, doi:10.1016/j.brainres.2009.09.083.
[57]	Boado, R.J.; Black, K.L.; Pardridge, W.M. Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Brain Res. Mol. Brain Res. 1994, 27, 51–57, doi:10.1016/0169-328X(94)90183-X.
[58]	Reitman, Z.J.; Yan, H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: Alterations at a crossroads of cellular metabolism. J. Natl. Cancer Inst. 2010, 102, 932–941, doi:10.1093/jnci/djq187.
[59]	Kim, W.; Liau, L.M. IDH mutations in human glioma. Neurosurg. Clin. N. Am. 2012, 23, 471–480, doi:10.1016/j.nec.2012.04.009.
[60]	Weller, M.; Wick, W.; von Deimling, A. Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas. Glia 2011, 59, 1200–1204, doi:10.1002/glia.21130.
[61]	Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.M.; Gallia, G.L.; et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321, 1807–1812, doi:10.1126/science.1164382.
[62]	Yan, H.; Parsons, D.W.; Jin, G.; McLendon, R.; Rasheed, B.A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G.J.; et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360, 765–773, doi:10.1056/NEJMoa0808710.
[63]	DeAngelis, L.M.; Mellinghoff, I.K. Virchow 2011 or how to ID(H) human glioblastoma. J. Clin. Oncol. 2011, 29, 4473–4474, doi:10.1200/JCO.2011.37.5873.
[64]	Watanabe, T.; Nobusawa, S.; Kleihues, P.; Ohgaki, H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 2009, 174, 1149–1153, doi:10.2353/ajpath.2009.080958.
[65]	Riemenschneider, M.J.; Jeuken, J.W.; Wesseling, P.; Reifenberger, G. Molecular diagnostics of gliomas: State of the art. Acta Neuropathol. 2010, 120, 567–584, doi:10.1007/s00401-010-0736-4.
[66]	Ward, P.S.; Patel, J.; Wise, D.R.; Abdel-Wahab, O.; Bennett, B.D.; Coller, H.A.; Cross, J.R.; Fantin, V.R.; Hedvat, C.V.; Perl, A.E.; et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17, 225–234, doi:10.1016/j.ccr.2010.01.020.
[67]	Boulahbel, H.; Duran, R.V.; Gottlieb, E. Prolyl hydroxylases as regulators of cell metabolism. Biochem. Soc. Trans. 2009, 37, 291–294, doi:10.1042/BST0370291.
[68]	Zhao, S.; Lin, Y.; Xu, W.; Jiang, W.; Zha, Z.; Wang, P.; Yu, W.; Li, Z.; Gong, L.; Peng, Y.; et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324, 261–265, doi:10.1126/science.1170944.
[69]	Andronesi, O.C.; Kim, G.S.; Gerstner, E.; Batchelor, T.; Tzika, A.A.; Fantin, V.R.; Vander Heiden, M.G.; Sorensen, A.G. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci. Transl. Med. 2012, 4, 116ra114.
[70]	Choi, C.; Ganji, S.K.; DeBerardinis, R.J.; Hatanpaa, K.J.; Rakheja, D.; Kovacs, Z.; Yang, X.L.; Mashimo, T.; Raisanen, J.M.; Marin-Valencia, I.; et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat. Med. 2012, 18, 624–629, doi:10.1038/nm.2682.
[71]	Kalinina, J.; Carroll, A.; Wang, L.; Yu, Q.; Mancheno, D.E.; Wu, S.; Liu, F.; Ahn, J.; He, M.; Mao, H.; et al. Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. J. Mol. Med (Berl.) 2012, 90, 1161–1171, doi:10.1007/s00109-012-0888-x.
[72]	Dang, L.; White, D.W.; Gross, S.; Bennett, B.D.; Bittinger, M.A.; Driggers, E.M.; Fantin, V.R.; Jang, H.G.; Jin, S.; Keenan, M.C.; et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010, 465, 966.
[73]	Lai, A.; Kharbanda, S.; Pope, W.B.; Tran, A.; Solis, O.E.; Peale, F.; Forrest, W.F.; Pujara, K.; Carrillo, J.A.; Pandita, A.; et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J. Clin. Oncol. 2011, 29, 4482–4490, doi:10.1200/JCO.2010.33.8715.
[74]	Turcan, S.; Rohle, D.; Goenka, A.; Walsh, L.A.; Fang, F.; Yilmaz, E.; Campos, C.; Fabius, A.W.; Lu, C.; Ward, P.S.; et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483, 479–483, doi:10.1038/nature10866.
[75]	Lu, C.; Ward, P.S.; Kapoor, G.S.; Rohle, D.; Turcan, S.; Abdel-Wahab, O.; Edwards, C.R.; Khanin, R.; Figueroa, M.E.; Melnick, A.; et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483, 474–478, doi:10.1038/nature10860.
[76]	Zielke, H.R.; Zielke, C.L.; Ozand, P.T. Glutamine: A major energy source for cultured mammalian cells. Fed. Proc. 1984, 43, 121–125.
[77]	Reitzer, L.J.; Wice, B.M.; Kennell, D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 1979, 254, 2669–2676.
[78]	Cory, J.G.; Cory, A.H. Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: Asparaginase treatment in childhood acute lymphoblastic leukemia. In vivo 2006, 20, 587–589.
[79]	Butler, E.B.; Zhao, Y.; Munoz-Pinedo, C.; Lu, J.; Tan, M. Stalling the engine of resistance: Targeting cancer metabolism to overcome therapeutic resistance. Cancer Res. 2013, 73, 2709–2717, doi:10.1158/0008-5472.CAN-12-3009.
[80]	DeBerardinis, R.J.; Mancuso, A.; Daikhin, E.; Nissim, I.; Yudkoff, M.; Wehrli, S.; Thompson, C.B. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. USA 2007, 104, 19345–19350.
[81]	Rajagopalan, K.N.; DeBerardinis, R.J. Role of glutamine in cancer: Therapeutic and imaging implications. J. Nucl. Med. 2011, 52, 1005–1008, doi:10.2967/jnumed.110.084244.
[82]	Daye, D.; Wellen, K.E. Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis. Semin. Cell Dev. Biol. 2012, 23, 362–369, doi:10.1016/j.semcdb.2012.02.002.
[83]	Lu, W.; Pelicano, H.; Huang, P. Cancer metabolism: Is glutamine sweeter than glucose? Cancer Cell 2010, 18, 199–200, doi:10.1016/j.ccr.2010.08.017.
[84]	Dang, C.V.; Le, A.; Gao, P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 2009, 15, 6479–6483, doi:10.1158/1078-0432.CCR-09-0889.
[85]	Rathore, M.G.; Saumet, A.; Rossi, J.F.; de Bettignies, C.; Tempe, D.; Lecellier, C.H.; Villalba, M. The NF-kappaB member p65 controls glutamine metabolism through miR-23a. Int. J. Biochem. Cell Biol. 2012, 44, 1448–1456, doi:10.1016/j.biocel.2012.05.011.
[86]	Wang, J.B.; Erickson, J.W.; Fuji, R.; Ramachandran, S.; Gao, P.; Dinavahi, R.; Wilson, K.F.; Ambrosio, A.L.; Dias, S.M.; Dang, C.V.; et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010, 18, 207–219, doi:10.1016/j.ccr.2010.08.009.
[87]	Kallenberg, K.; Bock, H.C.; Helms, G.; Jung, K.; Wrede, A.; Buhk, J.H.; Giese, A.; Frahm, J.; Strik, H.; Dechent, P.; et al. Untreated glioblastoma multiforme: Increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy. Radiology 2009, 253, 805–812, doi:10.1148/radiol.2533071654.
[88]	Rosati, A.; Marconi, S.; Pollo, B.; Tomassini, A.; Lovato, L.; Maderna, E.; Maier, K.; Schwartz, A.; Rizzuto, N.; Padovani, A.; et al. Epilepsy in glioblastoma multiforme: Correlation with glutamine synthetase levels. J. Neurooncol. 2009, 93, 319–324, doi:10.1007/s11060-008-9794-z.
[89]	Maxfield, F.R. Plasma membrane microdomains. Curr. Opin. Cell Biol. 2002, 14, 483–487, doi:10.1016/S0955-0674(02)00351-4.
[90]	Mukherjee, S.; Maxfield, F.R. Membrane domains. Annu. Rev. Cell Dev. Biol. 2004, 20, 839–866, doi:10.1146/annurev.cellbio.20.010403.095451.
[91]	Pomorski, T.; Hrafnsdottir, S.; Devaux, P.F.; van Meer, G. Lipid distribution and transport across cellular membranes. Semin. Cell Dev. Biol. 2001, 12, 139–148, doi:10.1006/scdb.2000.0231.
[92]	Van Meer, G. Membranes in motion. EMBO Rep. 2010, 11, 331–333, doi:10.1038/embor.2010.60.
[93]	Van Meer, G.; Voelker, D.R.; Feigenson, G.W. Membrane lipids: Where they are and how they behave. Nat. Rev. Mol. Cell Biol. 2008, 9, 112–124, doi:10.1038/nrm2330.
[94]	Menendez, J.A.; Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7, 763–777, doi:10.1038/nrc2222.
[95]	Zechner, R.; Strauss, J.G.; Haemmerle, G.; Lass, A.; Zimmermann, R. Lipolysis: Pathway under construction. Curr. Opin. Lipidol. 2005, 16, 333–340, doi:10.1097/01.mol.0000169354.20395.1c.
[96]	Abramson, H.N. The lipogenesis pathway as a cancer target. J. Med. Chem. 2011, 54, 5615–5638, doi:10.1021/jm2005805.
[97]	Grossi-Paoletti, E.; Paoletti, P.; Fumagalli, R. Lipids in brain tumors. J. Neurosurg. 1971, 34, 454–455, doi:10.3171/jns.1971.34.3.0454.
[98]	Podo, F. Tumour phospholipid metabolism. NMR Biomed. 1999, 12, 413–439, doi:10.1002/(SICI)1099-1492(199911)12:7<413::AID-NBM587>3.0.CO;2-U.
[99]	Santos, C.R.; Schulze, A. Lipid metabolism in cancer. FEBS J. 2012, 279, 2610–2623, doi:10.1111/j.1742-4658.2012.08644.x.
[100]	Yoon, S.; Lee, M.Y.; Park, S.W.; Moon, J.S.; Koh, Y.K.; Ahn, Y.H.; Park, B.W.; Kim, K.S. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J. Biol. Chem. 2007, 282, 26122–26131.
[101]	Gopal, K.; Grossi, E.; Paoletti, P.; Usardi, M. Lipid composition of human intracranial tumors: A biochemical study. Acta Neurochir. (Wien) 1963, 11, 333–347, doi:10.1007/BF01402012.
[102]	Horton, J.D.; Goldstein, J.L.; Brown, M.S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 2002, 109, 1125–1131.
[103]	Shimano, H. Sterol regulatory element-binding proteins (SREBPs): Transcriptional regulators of lipid synthetic genes. Prog. Lipid Res. 2001, 40, 439–452, doi:10.1016/S0163-7827(01)00010-8.
[104]	Brown, M.S.; Goldstein, J.L. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997, 89, 331–340, doi:10.1016/S0092-8674(00)80213-5.
[105]	Nohturfft, A.; DeBose-Boyd, R.A.; Scheek, S.; Goldstein, J.L.; Brown, M.S. Sterols regulate cycling of SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and Golgi. Proc. Natl. Acad. Sci. USA 1999, 96, 11235–11240, doi:10.1073/pnas.96.20.11235.
[106]	Sakai, J.; Duncan, E.A.; Rawson, R.B.; Hua, X.; Brown, M.S.; Goldstein, J.L. Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment. Cell 1996, 85, 1037–1046, doi:10.1016/S0092-8674(00)81304-5.
[107]	Zelenski, N.G.; Rawson, R.B.; Brown, M.S.; Goldstein, J.L. Membrane topology of S2P, a protein required for intramembranous cleavage of sterol regulatory element-binding proteins. J. Biol. Chem. 1999, 274, 21973–21980.
[108]	Espenshade, P.J.; Cheng, D.; Goldstein, J.L.; Brown, M.S. Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-binding proteins. J. Biol. Chem. 1999, 274, 22795–22804.
[109]	Hua, X.; Yokoyama, C.; Wu, J.; Briggs, M.R.; Brown, M.S.; Goldstein, J.L.; Wang, X. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc. Natl. Acad. Sci. USA 1993, 90, 11603–11607.
[110]	Jeon, T.I.; Osborne, T.F. SREBPs: Metabolic integrators in physiology and metabolism. Trends Endocrinol. Metab. 2012, 23, 65–72, doi:10.1016/j.tem.2011.10.004.
[111]	Shao, W.; Espenshade, P.J. Expanding Roles for SREBP in Metabolism. Cell Metab. 2012, 16, 414–419, doi:10.1016/j.cmet.2012.09.002.
[112]	Ettinger, S.L.; Sobel, R.; Whitmore, T.G.; Akbari, M.; Bradley, D.R.; Gleave, M.E.; Nelson, C.C. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 2004, 64, 2212–2221, doi:10.1158/0008-5472.CAN-2148-2.
[113]	Yang, Y.; Morin, P.J.; Han, W.F.; Chen, T.; Bornman, D.M.; Gabrielson, E.W.; Pizer, E.S. Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp. Cell Res. 2003, 282, 132–137, doi:10.1016/S0014-4827(02)00023-X.
[114]	Von Roemeling, C.A.; Marlow, L.A.; Wei, J.J.; Cooper, S.J.; Caulfield, T.R.; Wu, K.; Tan, W.W.; Tun, H.W.; Copland, J.A. Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma. Clin. Cancer Res. 2013, 19, 2368–2380, doi:10.1158/1078-0432.CCR-12-3249.
[115]	Maxfield, F.R.; Tabas, I. Role of cholesterol and lipid organization in disease. Nature 2005, 438, 612–621, doi:10.1038/nature04399.
[116]	Tosi, M.R.; Tugnoli, V. Cholesteryl esters in malignancy. Clin. Chim. Acta 2005, 359, 27–45, doi:10.1016/j.cccn.2005.04.003.
[117]	Tugnoli, V.; Tosi, M.R. Cholesteryl ester detection in a human urothelial carcinoma. Clin. Chim. Acta 2005, 360, 208–210, doi:10.1016/j.cccn.2005.05.012.
[118]	Tugnoli, V.; Tosi, M.R.; Tinti, A.; Trinchero, A.; Bottura, G.; Fini, G. Characterization of lipids from human brain tissues by multinuclear magnetic resonance spectroscopy. Biopolymers. 2001, 62, 297–306, doi:10.1002/bip.10005.
[119]	Tugnoli, V.; Bottura, G.; Fini, G.; Reggiani, A.; Tinti, A.; Trinchero, A.; Tosi, M.R. 1H-NMR and 13C-NMR lipid profiles of human renal tissues. Biopolymers 2003, 72, 86–95, doi:10.1002/bip.10299.
[120]	Yates, A.J.; Thompson, D.K.; Boesel, C.P.; Albrightson, C.; Hart, R.W. Lipid composition of human neural tumors. J. Lipid Res. 1979, 20, 428–436.
[121]	Rudling, M.J.; Angelin, B.; Peterson, C.O.; Collins, V.P. Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. Cancer Res. 1990, 50, 483–487.
[122]	Goldstein, J.L.; Brown, M.S. The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 431–438, doi:10.1161/ATVBAHA.108.179564.
[123]	Zelcer, N.; Tontonoz, P. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 2006, 116, 607–614, doi:10.1172/JCI27883.
[124]	Calkin, A.C.; Tontonoz, P. Liver x receptor signaling pathways and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 1513–1518, doi:10.1161/ATVBAHA.109.191197.
[125]	Vedin, L.L.; Lewandowski, S.A.; Parini, P.; Gustafsson, J.A.; Steffensen, K.R. The oxysterol receptor LXR inhibits proliferation of human breast cancer cells. Carcinogenesis 2009, 30, 575–579, doi:10.1093/carcin/bgp029.
[126]	Zelcer, N.; Hong, C.; Boyadjian, R.; Tontonoz, P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009, 325, 100–104, doi:10.1126/science.1168974.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413